Favorable response to daratumumab combination therapy in patients with multiple myeloma with an immature phenotype: a report from the J-CHARGE study group
- 09.11.2025
- Original Article
- Verfasst von
- Noriyoshi Iriyama
- Hitomi Nakayama
- Masaru Nakagawa
- Atsushi Takahata
- Eriko Sato
- Motoki Takano
- Keigo Okada
- Kohtaro Toyama
- Toshiaki Hayashi
- Takashi Abe
- Keisuke Tanaka
- Yasuhiko Senpuku
- Yuki Osada
- Junichi Watanabe
- Koh Yamamoto
- Yasunobu Sekiguchi
- Gaku Oshikawa
- Yuta Kimura
- Michihide Tokuhira
- Ken Suzuki
- Takashi Kumagai
- Takayuki Ikezoe
- Shigeo Toyota
- Katsuhiro Miura
- Tomonori Nakazato
- Takehiko Mori
- Erschienen in
- International Journal of Hematology
Abstract
Aim and purpose
This study aimed to investigate the relationship between myeloma cell maturity, clinical profiles, and treatment outcomes in patients with multiple myeloma (MM).
Patients and methods
The J-CHARGE-MM database includes data from 1200 MM patients diagnosed between January 2011 and January 2023. Immunophenotyping by flow cytometry using antibodies against CD38, CD49e, and MPC-1 was used to evaluate myeloma cell maturity.
Results
Out of 969 patients evaluable for myeloma cell maturity, 115 were classified as mature type, 626 as intermediate type, and 228 as immature type. Patients with the immature type were more likely to have the IgG type and 1q21 gain/amplification. Treatment response and outcome analysis showed that patients with the immature type had lower response rates and worse time to next treatment (TTNT) with bortezomib-based therapy compared to those with the mature or intermediate type. Lenalidomide-based therapy partially mitigated the adverse impact of the immature type. However, daratumumab combination therapy showed higher response rates and better TTNT, which was almost equivalent between the mature/intermediate and immature types.
Conclusion
Stratifying patients with MM based on myeloma cell maturity provides meaningful information for choosing the best treatment strategy and improving patient outcomes.
Anzeige
- Titel
- Favorable response to daratumumab combination therapy in patients with multiple myeloma with an immature phenotype: a report from the J-CHARGE study group
- Verfasst von
-
Noriyoshi Iriyama
Hitomi Nakayama
Masaru Nakagawa
Atsushi Takahata
Eriko Sato
Motoki Takano
Keigo Okada
Kohtaro Toyama
Toshiaki Hayashi
Takashi Abe
Keisuke Tanaka
Yasuhiko Senpuku
Yuki Osada
Junichi Watanabe
Koh Yamamoto
Yasunobu Sekiguchi
Gaku Oshikawa
Yuta Kimura
Michihide Tokuhira
Ken Suzuki
Takashi Kumagai
Takayuki Ikezoe
Shigeo Toyota
Katsuhiro Miura
Tomonori Nakazato
Takehiko Mori
- Publikationsdatum
- 09.11.2025
- Verlag
- Springer Nature Singapore
- Erschienen in
-
International Journal of Hematology
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774 - DOI
- https://doi.org/10.1007/s12185-025-04100-2
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.
